Treatment of newly diagnosed multiple myeloma: Advances in current therapy

Medical Oncology

Volumn 27, Issue SUPPL. 1, 2010, Pages

  Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

Author keywords

Multiple myeloma; Risk stratification; Survival

Indexed keywords

ACETYLSALICYLIC ACID; AMIFOSTINE; BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; HOLMIUM; INTERFERON; LENALIDOMIDE; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; SAMARIUM; STEROID; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DRUG MEGADOSE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REHYDRATION; REVIEW; STEM CELL TRANSPLANTATION; THROMBOSIS;

ANTINEOPLASTIC PROTOCOLS; DISEASE MANAGEMENT; HUMANS; MULTIPLE MYELOMA; PROGNOSIS;

EID: 77954085499     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9370-1     Document Type: Review

References (68)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics CA Cancer J Clin. 59 225 249 10.3322/caac.20006 19474385
2. RA Kyle SV Rajkumar 2004 Multiple myeloma N Engl J Med 351 1860 1873 10.1056/NEJMra041875 15509819 (Pubitemid 39426321)
3. RA Kyle SV Rajkumar 2008 Multiple myeloma Blood 111 2962 2972 10.1182/blood-2007-10-078022 18332230
4. RA Kyle SV Rajkumar 2009 Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 3 9 10.1038/leu.2008.291 18971951
5. H Brenner A Gondos D Pulte 2008 Recent major improvement in long-term survival of younger patients with multiple myeloma Blood 111 2521 2526 10.1182/blood-2007-08-104984 17901246
6. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 10.1182/blood-2007-10-116129 17975015
7. SV Rajkumar 2008 Treatment of myeloma: cure vs. control Mayo Clinic Proc 83 1142 1145 10.4065/83.10.1142
8. O Landgren RA Kyle RM Pfeiffer, et al. 2009 Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 113 5412 5417 10.1182/blood-2008-12-194241 19179464
9. RA Kyle TM Therneau SV Rajkumar, et al. 2006 Prevalence of monoclonal gammopathy of undetermined significance N Engl J Med 354 1362 1369 10.1056/NEJMoa054494 16571879
10. R Kyle E Remstein T Therneau, et al. 2005 The natural history of smoldering (asymptomatic) multiple myeloma Blood 106 949a (A3396)
11. RA Kyle TM Therneau SV Rajkumar, et al. 2002 A long-term study of prognosis of monoclonal gammopathy of undetermined significance N Engl J Med 346 564 569 10.1056/NEJMoa01133202 11856795 (Pubitemid 34438817)
12. A Dispenzieri RA Kyle JA Katzmann, et al. 2008 Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Blood 111 785 789 10.1182/blood-2007-08-108357 17942755
13. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008.
14. PR Greipp JF San Miguel BG Durie, et al. 2005 International staging system for multiple myeloma J Clin Oncol 23 3412 3420 10.1200/JCO.2005.04.242 15809451
15. R Fonseca D Harrington MM Oken, et al. 2002 Biological and prognostic significance of interphase fluorescence is situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: an Eastern Cooperative Oncology Group Study Cancer Res 62 715 720 11830525
16. AK Stewart PL Bergsagel PR Greipp, et al. 2007 A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy Leukemia 21 529 534 10.1038/sj.leu.2404516 17230230
17. A Dispenzieri SV Rajkumar MA Gertz, et al. 2007 Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement Mayo Clin Proc 82 323 341 10.4065/82.3.323 17352369
18. M Attal JL Harousseau AM Stoppa, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 91 97 10.1056/NEJM199607113350204 8649495 (Pubitemid 26240110)
19. JA Child GJ Morgan FE Davies, et al. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 1883 10.1056/NEJMoa022340 12736280 (Pubitemid 36532313)
20. JP Fermand P Ravaud S Chevret, et al. 1998 High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 92 3131 3136 9787148
21. Kumar S, Lacy M, Dispenzieri A, et al. Autologous stem cell transplantation for multiple myeloma in patients over 70 years: a matched comparison with patients under 65 years. ASH Annual Meeting Abstracts. 2005;106:1173.
22. BG Durie JL Harousseau JS Miguel, et al. 2006 International uniform response criteria for multiple myeloma Leukemia 20 1467 1473 10.1038/sj.leu.2404284 16855634 (Pubitemid 44264086)
23. S Kumar MQ Lacy A Dispenzieri, et al. 2004 High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy Bone Marrow Transplant 34 161 167 10.1038/sj.bmt.1704545 15133489 (Pubitemid 39077108)
24. SV Rajkumar S Hayman MA Gertz, et al. 2002 Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 4319 4323 10.1200/JCO.2002.02.116 12409330 (Pubitemid 35266292)
25. SV Rajkumar E Blood DH Vesole R Fonseca PR Greipp 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 431 436 10.1200/JCO.2005.03.0221 16365178 (Pubitemid 46630462)
26. SV Rajkumar L Rosinol M Hussein, et al. 2008 Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 2171 2177 10.1200/JCO.2007.14.1853 18362366
27. M Cavo E Zamagni P Tosi, et al. 2005 Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 35 39 10.1182/blood-2005-02-0522 15761019 (Pubitemid 40967171)
28. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone + Thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (mm): a randomized trial. ASH Annual Meeting Abstracts. 2006;108:57.
29. MQ Lacy MA Gertz A Dispenzieri, et al. 2007 Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma Mayo Clinic Proc 82 1179 1184 10.4065/82.10.1179
30. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Annual Meeting Abstracts. 2007;110:77.
31. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol 2007 ASCO Annual Meeting Abstracts 2007;25 (18S):LBA8025.
32. Kumar S, Hayman SR, Buadi FK, et al. Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma. ASH Annual Meeting Abstracts. 2007;110:190.
33. S Jagannath BG Durie J Wolf, et al. 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 776 783 10.1111/j.1365-2141.2005.05540.x 15953004 (Pubitemid 40904528)
34. Harousseau JL, Mathiot C, Attal M, et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. ASH Annual Meeting Abstracts. 2007;110:450.
35. M Cavo P Tacchetti F Patriarca, et al. 2008 Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide- dexamethasone in newly diagnosed multiple myeloma Blood (ASH Annual Meeting Abstracts) 112 158
36. P Richardson S Lonial A Jakubowiak, et al. 2008 Lenalidomide, Bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study Blood (ASH Annual Meeting Abstracts) 112 92
37. S Kumar IW Flinn SJ Noga, et al. 2008 Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the Phase I/II Multi-Center EVOLUTION Study Blood (ASH Annual Meeting Abstracts) 112 93
38. J Blade L Rosinol A Sureda JP Fermand S Katsahian M Divine, et al. 2005 High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe J Clin Oncol 23 9227 9233 10.1200/JCO.2005.03.0551
39. B Barlogie RA Kyle KC Anderson, et al. 2006 Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup Trial S9321 J Clin Oncol 24 929 936 10.1200/JCO.2005.04.5807 16432076 (Pubitemid 46638847)
40. J Blade L Rosinol A Sureda, et al. 2005 High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA Blood 106 3755 3759 10.1182/blood-2005-03-1301 16105975 (Pubitemid 41739009)
41. A Palumbo S Bringhen MT Petrucci, et al. 2004 Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial Blood 15 3052 3057 10.1182/blood-2004-02-0408 (Pubitemid 39507119)
42. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern cooperative oncology group. ASH Annual Meeting Abstracts. 2008;112:74.
43. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007.
44. S Lonial J Kaufman C Torre, et al. 2008 A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: the effect of sequence of administration Blood (ASH Annual Meeting Abstracts) 112 3332
45. S Giralt W Bensinger M Goodman, et al. 2003 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials Blood 102 2684 2691 10.1182/blood-2002-10-3250 12730103 (Pubitemid 37193613)
46. M Attal JL Harousseau T Facon, et al. 2003 Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2495 2502 10.1056/NEJMoa032290 14695409 (Pubitemid 38010075)
47. M Cavo P Tosi E Zamagni, et al. 2007 Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study J Clin Oncol 25 2434 2441 10.1200/JCO.2006.10.2509 17485707 (Pubitemid 46999214)
48. JP Fermand C Alberti JP Marolleau 2003 Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) Hematol J 4 Suppl 1 S59
49. M Attal J-L Harousseau S Leyvraz, et al. 2006 Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 3289 3294 10.1182/blood-2006-05-022962 10.1182/blood-2006-05-022962 16873668
50. BB Bjorkstrand P Ljungman H Svensson, et al. 1996 Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 88 4711 4718 8977265 (Pubitemid 26419156)
51. F Garban M Attal M Michallet, et al. 2006 Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Blood 107 3474 3480 10.1182/blood-2005-09-3869 10.1182/blood-2005-09-3869 16397129
52. B Bruno M Rotta F Patriarca, et al. 2007 A comparison of allografting with autografting for newly diagnosed myeloma N Engl J Med 356 1110 1120 10.1056/NEJMoa065464 17360989 (Pubitemid 46425595)
53. Myeloma Trialists' Collaborative Group 1998 Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials J Clin Oncol 16 3832 3842
54. A Palumbo S Bringhen T Caravita, et al. 2006 Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 825 831 10.1016/S0140-6736(06)68338-4 16530576 (Pubitemid 43363369)
55. Facon T, Mary JY, Hulin C, et al. Randomized clinical trial comparing melphalan-prednisone (MP), MP-Thalidomide (MP-THAL) and high-dose therapy using melphalan 100 MG/M2 (MEL100) for newly diagnosed myeloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial on 350 patients. Blood. 2004;104:63a (A206).
56. JF San Miguel R Schlag NK Khuageva, et al. 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 906 917 10.1056/NEJMoa0801479 18753647
57. A Palumbo S Bringhen D Rossi, et al. 2008 A prospective, randomized, phase iii study of bortezomib, melphalan, prednisone and thalidomide (vmpt) versus bortezomib, melphalan and prednisone (vmp) in elderly newly diagnosed myeloma patients Blood (ASH Annual Meeting Abstracts) 112 652
58. A Palumbo P Falco P Corradini, et al. 2007 Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network J Clin Oncol 25 4459 4465 10.1200/JCO.2007.12. 3463 17785703 (Pubitemid 350063804)
59. MQ Lacy A Dispenzieri MA Gertz, et al. 2006 Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma Mayo Clinic Proc 81 1047 1053 10.4065/81.8.1047
60. RA Kyle GC Yee MR Somerfield, et al. 2007 American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma J Clin Oncol 25 2464 2472 10.1200/JCO.2007.12.1269 17515569 (Pubitemid 46999218)
61. R Knight RJ DeLap JB Zeldis 2006 Lenalidomide and venous thrombosis in multiple myeloma N Engl J Med 354 2079 2080 10.1056/NEJMc053530 16687729
62. L Pillon RS Sweeting A Arora, et al. 2008 Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis? Kidney Int 74 956 961 10.1038/ki.2008.138 18418353
63. E Alyea E Weller R Schlossman, et al. 2003 Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect Bone Marrow Transplant 32 1145 1151 10.1038/sj.bmt.1704289 14647268 (Pubitemid 38072327)
64. M Arora PB McGlave LJ Burns, et al. 2005 Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma Bone Marrow Transplant 35 1133 1140 10.1038/sj.bmt.1704968 15834435 (Pubitemid 40895168)
65. J Kuruvilla JD Shepherd HJ Sutherland, et al. 2007 Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma Biol Blood Marrow Transplant 13 925 931 10.1016/j.bbmt.2007.04.006 17640596 (Pubitemid 47064359)
66. C Hulin T Facon P Rodon, et al. 2009 Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial J Clin Oncol 27 3664 3670 10.1200/JCO.2008.21.0948 19451428
67. A Waage P Gimsing G Juliusson, et al. 2007 Melphalan-prednisone- thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial Blood (ASH Annual Meeting Abstracts) 110 78
68. P Wijermans M Schaafsma Y van Norden, et al. 2008 Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study Blood (ASH Annual Meeting Abstracts) 112 649